ATNX - Athenex's oral paclitaxel rejected by UK's regulatory agency for breast cancer
- The UK's Medicines and Healthcare Products Regulatory Agency has declined to approve Athenex's ( NASDAQ: ATNX ) oral paclitaxel for metastatic breast cancer .
- The rejection was due to chemistry, manufacturing, and control ("CMC") issues, and not due to efficacy or safety concerns, according to the company.
- Athenex said the CMC issues are addressable.
- Seeking Alpha's Quant Ratings views Athenex ( ATNX ) as a hold with top marks for valuation and revisions .
For further details see:
Athenex's oral paclitaxel rejected by UK's regulatory agency for breast cancer